Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares hit a new 52-week low on Wednesday . The company traded as low as $15.28 and last traded at $15.27, with a volume of 7,864,063 shares changing hands. The stock had previously closed at $15.41.

A number of brokerages recently weighed in on TEVA. Royal Bank Of Canada reissued an “underperform” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday. ValuEngine downgraded Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $21.00 price objective (down from $28.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, August 31st. Finally, TheStreet downgraded Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. Four investment analysts have rated the stock with a sell rating, twenty have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $34.50.

The company’s market cap is $15.67 billion. The company’s 50 day moving average is $22.43 and its 200 day moving average is $29.47.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.25 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 2.21%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -15.36%.

A number of large investors have recently modified their holdings of TEVA. Capital Research Global Investors grew its position in Teva Pharmaceutical Industries Limited by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after buying an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. grew its position in Teva Pharmaceutical Industries Limited by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after buying an additional 6,685,844 shares in the last quarter. FMR LLC grew its position in Teva Pharmaceutical Industries Limited by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after buying an additional 6,115,853 shares in the last quarter. Capital World Investors grew its position in Teva Pharmaceutical Industries Limited by 41.9% during the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after buying an additional 3,268,200 shares in the last quarter. Finally, Alliancebernstein L.P. grew its position in Teva Pharmaceutical Industries Limited by 32.3% during the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock worth $378,688,000 after buying an additional 2,782,257 shares in the last quarter. 56.87% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Sets New 52-Week Low at $15.28” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/06/teva-pharmaceutical-industries-limited-teva-sets-new-52-week-low-at-15-28.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.